91 related articles for article (PubMed ID: 5427314)
1. Drug interaction? Orphenadrine with propoxyphene.
Pearson RE; Salter FJ
N Engl J Med; 1970 May; 282(21):1215. PubMed ID: 5427314
[No Abstract] [Full Text] [Related]
2. Orphenadrine and propoxyphene.
Puckett WH; Visconti JA
N Engl J Med; 1970 Sep; 283(10):544. PubMed ID: 5434148
[No Abstract] [Full Text] [Related]
3. Orphenadrine and propoxyphene.
Renforth W
N Engl J Med; 1970 Oct; 283(18):998. PubMed ID: 5470261
[No Abstract] [Full Text] [Related]
4. Evaluation of drug efficacy by a preference technic.
Jick H; Slone D; Dinan B; Muench H
N Engl J Med; 1966 Dec; 275(25):1399-403. PubMed ID: 5956365
[No Abstract] [Full Text] [Related]
5. Propoxyphene dependence and withdrawal.
Strode SW
Am Fam Physician; 1985 Sep; 32(3):105-8. PubMed ID: 4036770
[TBL] [Abstract][Full Text] [Related]
6. Why pick on propoxyphene? The evidence demands it.
Hutchison LC
J Ark Med Soc; 2010 Aug; 107(2):36-7. PubMed ID: 20806582
[TBL] [Abstract][Full Text] [Related]
7. Lack of toxicity of high dose propoxyphene napsylate when used for maintenance treatment of addiction.
Woody GE; McLellan AT; O'Brien CP; Tennant FS; Mintz J
Clin Toxicol; 1980 Jun; 16(4):473-8. PubMed ID: 6105935
[No Abstract] [Full Text] [Related]
8. FDA raises safety issues concerning propoxyphene.
Aschenbrenner DS
Am J Nurs; 2010 Jan; 110(1):59-60. PubMed ID: 20032671
[No Abstract] [Full Text] [Related]
9. Propoxyphene and congenital malformations.
Barrow MV; Souder DE
JAMA; 1971 Sep; 217(11):1551-2. PubMed ID: 5109758
[No Abstract] [Full Text] [Related]
10. Oral treatment of skeletal muscle spasm with fluphenazine alone and combined with orphenadrine.
Guidotti FP; Dilluvio V
Curr Ther Res Clin Exp; 1965 Nov; 7(11):693-6. PubMed ID: 4953689
[No Abstract] [Full Text] [Related]
11. Propoxyphene use and risk for hip fractures in older adults.
Kamal-Bahl SJ; Stuart BC; Beers MH
Am J Geriatr Pharmacother; 2006 Sep; 4(3):219-26. PubMed ID: 17062322
[TBL] [Abstract][Full Text] [Related]
12. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity.
Barkin RL; Barkin SJ; Barkin DS
Am J Ther; 2006; 13(6):534-42. PubMed ID: 17122535
[TBL] [Abstract][Full Text] [Related]
13. Non-sustained ventricular tachycardia due to low-dose orphenadrine.
Dilaveris P; Pantazis A; Vlasseros J; Gialafos J
Am J Med; 2001 Oct; 111(5):418-9. PubMed ID: 11599527
[No Abstract] [Full Text] [Related]
14. D-propoxyphene and dipyrone co-administration produces greater antinociception and fewer adverse effects than single treatments in rats.
Silva-Moreno A; López-Muñoz FJ; Cruz SL
Eur J Pharmacol; 2009 Apr; 607(1-3):84-90. PubMed ID: 19232342
[TBL] [Abstract][Full Text] [Related]
15. Recurrent episodes of hypoglycemia induced by propoxyphene.
Wiederholt IC; Genco M; Foley JM
Neurology; 1967 Jul; 17(7):703-6. PubMed ID: 6067489
[No Abstract] [Full Text] [Related]
16. Propoxyphene hydrochloride (Darvon) and Darvon compounds.
Med Lett Drugs Ther; 1970 Jan; 12(2):5-6. PubMed ID: 5510011
[No Abstract] [Full Text] [Related]
17. Pulmonary arteriole foreign body granulomata associated with angiomatoids resulting from the intravenous injection of oral medications, e. g., propoxyphene hydrochloride (Darvon).
Butz WC
J Forensic Sci; 1969 Jul; 14(3):317-26. PubMed ID: 5802944
[No Abstract] [Full Text] [Related]
18. Propoxyphene and pain management in the elderly.
Mort JR; Schroeder SD
S D Med; 2009 Nov; 62(11):433-5. PubMed ID: 20128173
[TBL] [Abstract][Full Text] [Related]
19. Dextropropoxyphene: withdrawal from the US market requested: harmful drug.
Prescrire Int; 2009 Aug; 18(102):166-7. PubMed ID: 19746529
[No Abstract] [Full Text] [Related]
20. [Clinical evaluation of d-propoxyphene napsylate (S-9700) as an anesthetic premedicant].
Miyazaki M; Okuno Y; Goto S; Kodama H
Masui; 1972 Mar; 21(3):199-205. PubMed ID: 4555736
[No Abstract] [Full Text] [Related]
[Next] [New Search]
